There has been significant progress in managing men with metastatic hormone-sensitive prostate cancer with unprecedented prolongation of overall survival with therapy intensification. Critical to this progress was maximizing the antitumor strategy that is based on continuous androgen deprivation combined with docetaxel or abiraterone + prednisone. Intermittent androgen deprivation as previously tested has not lived up to the expectations and hence is not considered an optimal standard of care option. As therapy is being intensified and patients are living longer, its role moving forward should be critically evaluated in prospective well-designed clinical trials.
- Intermittent androgen deprivation
- Prostate cancer
ASJC Scopus subject areas